A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy (MINORE)

  • End date
    Jan 17, 2025
  • participants needed
  • sponsor
    Hoffmann-La Roche
Updated on 12 September 2023
clinically isolated syndrome


This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

Condition Multiple Sclerosis, Clinically Isolated Syndrome
Treatment Ocrelizumab
Clinical Study IdentifierNCT04998812
SponsorHoffmann-La Roche
Last Modified on12 September 2023


Yes No Not Sure

Inclusion Criteria

Diagnosis of MS or CIS (in line with the locally approved indications)
Currently pregnant with singleton pregnancy at gestational week ≤30 at enrolment
Documentation that first and second obstetric ultrasound has been conducted before enrolment during the screening period
Documentation that the last exposure to ocrelizumab occurred up to 6 months before the LMP before the woman became pregnant OR during the first trimester of pregnancy

Exclusion Criteria

Last exposure to ocrelizumab >6 months before the woman's LMP or later than the first trimester of pregnancy
Gestational age at enrolment >30 weeks
Non-singleton pregnancy
Received the last dose of ocrelizumab at a different posology other than per the local prescribing information
Lack of access to ultrasound pre-natal care as part of standard clinical practice
Prior or current obstetric/gynecological conditions associated with adverse pregnancy outcomes
Pre-pregnancy body mass index >35 kg/m2
Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
Prior or current history of primary or secondary immunodeficiency, or woman in an otherwise severely immunocompromised state
Significant and uncontrolled disease that may preclude a woman from participating in the study
Women with known active malignancies or being actively monitored for recurrence of malignancy including solid tumors and hematological malignancies
Prior or current history of alcohol or drug abuse, or current use of tobacco
Positive screening tests for hepatitis B
Treatment with drugs known to have teratogenic effects
Planned treatment with interferons, glatiramer acetate, or pulsed corticosteroids as a bridging therapy after the last ocrelizumab dose and throughout pregnancy
Treatment with disease-modifying therapies for MS within their respective half-lives prior to the last ocrelizumab dose or prior to the LMP
Treatment with teriflunomide within the last two years, unless measured plasma concentrations are <0.02 mg/L. If levels are >0.02 mg/L or not known, an accelerated elimination procedure is required
Treatment with natalizumab within 12 weeks prior to the LMP
Treatment with any investigational agent within 6 months or five half-lives of the investigational drug prior to the last ocrelizumab dose or prior to the LMP
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note